New integrated long-term glucose monitoring device

The US Food and Drug Administration (FDA) has for the first time approved the sale of the Eversense AP CGM (a Senseonics company) Long-Term Blood Glucose Monitoring System with labelling for integration into automated insulin delivery systems.  The sensor, contains dexamethasone to reduce inflammation at the implantation site.

The Eversense AP CGM includes a fully implantable sensor that contains dexamethasone. The drug is gradually released into the skin to reduce inflammation at the implantation site.

A single incision is enough to implant the sensor, after which the device can work for six months, transmitting the information received to a special application on a mobile phone. Experts believe that the system will eliminate the need for finger blood tests for diabetes, providing accurate real-time glycaemic control.